Skip to main content
MyDeficiencies

Sumatriptan

triptan, selective serotonin 5-HT1B/1D receptor agonist

Also sold as Imitrex, Onzetra, Zembrace, Sumavel.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Sumatriptan carries no classical nutrient-depletion mechanism. It is not metabolized by any CYP450 enzyme and does not induce or inhibit CYP450 metabolism; it is cleared predominantly by monoamine oxidase A (MAO-A) to an inactive indole acetic acid metabolite, with roughly a fifth of a dose excreted unchanged in urine. The regulatory label documents no chelation, no gastric-pH change, no renal electrolyte wasting, and no bile-acid or transporter-mediated absorption interference. Just as important, sumatriptan is taken acutely and intermittently, as needed for individual migraine or cluster-headache attacks, not as a chronic daily medication. Nearly all classical drug-nutrient depletion mechanisms (enzyme induction, sustained renal wasting, chronic malabsorption) require sustained, repeated exposure to produce a measurable deficit, and that exposure pattern is largely absent here. This acute-use framework, not the chronic-daily-dosing framework used for most drugs in this series, is the correct lens for every finding below.

triptan, selective serotonin 5-HT1B/1D receptor agonist · ATC N02CC01 · also sold as Imitrex and Treximet (with naproxen) and Onzetra and Zembrace and Sumavel and generics · reviewed 2026-09-29. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Sumatriptan in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden, preclinical hepatotoxicity model, sumatriptan-specific, upgraded on repair pass

Yellow — Low

See study details

The same sumatriptan-specific hepatotoxicity study used under Oxidative stress directly measured mitochondrial membrane potential decline and lysosomal membrane damage in sumatriptan-exposed hepatocytes, a mechanistic signal, not an established clinical mitochondrial-toxicity concern at approved human dosing.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative findings: None identified specific to mitochondrial burden. The label's own data, no labeled hepatotoxicity and no clinically meaningful pharmacokinetic change in mild-to-moderate hepatic impairment, are indirect counter-evidence against a clinically significant mitochondrial-toxicity effect at approved human dosing, though they do not directly measure mitochondrial membrane potential. A dedicated search for a second, independent mitochondrial-burden source (beyond this study) was completed this repair pass via Crossref and OpenAlex single-record lookups and found none; see Sources.
  • At-risk subgroups: None established at approved human dosing; this is a preclinical, mechanistic-tier signal generated at a supraphysiological in vitro concentration chosen specifically to produce measurable cytotoxicity, not at an exposure level reached by therapeutic dosing.

Regulatory status

Not addressed in the label; hepatic injury and mitochondrial toxicity are not labeled adverse reactions, and the label's hepatic-impairment language concerns clearance in patients with pre-existing liver disease, not sumatriptan-induced mitochondrial injury.

Population evidence

Tier B: the same in vitro hepatotoxicity study already cited under Oxidative stress (Khalili Fard J, Hamzeiy H, Sattari M, Eghbal MA. Protective Roles of N-acetyl Cysteine and/or Taurine against Sumatriptan-Induced Hepatotoxicity. Advanced Pharmaceutical Bulletin, 2016), confirmed Gold open access (CC-BY) and read in full during this 2026-09-29 repair pass via the publisher's own PDF and an OpenAlex single-record lookup, resolving the citation-completeness gap flagged in the original Oxidative stress entry. Freshly isolated parenchymal hepatocytes from male Sprague-Dawley rats (250 to 320 g) were exposed to sumatriptan at its calculated LC50 of 5 mM (50% membrane lysis within 120 minutes). At 5 mM, 120 minutes, versus control: cytotoxicity rose from 17 plus or minus 2% to 48 plus or minus 3%; mitochondrial membrane potential fell from 97 plus or minus 3% to 65 plus or minus 2% of control; lysosomal membrane damage, by acridine orange redistribution, rose from 9.9 plus or minus 3 to 39.5 plus or minus 3 intensity units; lipid peroxidation (TBARS) rose from 0.091 plus or minus 0.005 to 0.181 plus or minus 0.013 micromolar per 10^6 cells; cellular glutathione fell from 51.5 plus or minus 2.1 to 38.6 plus or minus 1.9 nmol per 10^6 cells. Taurine and N-acetylcysteine co-treatment significantly reduced all of these markers (p less than 0.05).

Mechanism

Named and directly measured: sumatriptan-induced free-radical generation depletes cellular glutathione, and the resulting oxidative stress produces measurable mitochondrial membrane potential loss and lysosomal membrane damage in hepatocytes, at a concentration the study itself uses as a cytotoxicity-screening exposure rather than a physiological plasma level (see framing caution).

Counter-evidence held on record

Preclinical, in vitro, and concentration-selected for cytotoxicity screening (LC50, 5 mM); do not present as an established human mitochondrial-toxicity risk from approved sumatriptan dosing, which produces peak plasma concentrations far below this in vitro exposure. No mitochondrial-support supplementation (CoQ10, carnitine, or similar) is indicated on this basis, and sumatriptan's acute, as-needed dosing pattern further limits any cumulative mitochondrial burden compared with a medication taken daily.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress, preclinical hepatotoxicity model only

Yellow — Low

See study details

A preclinical hepatotoxicity study found that antioxidant co-treatment protected against sumatriptan-induced liver injury, a mechanistic signal for oxidative stress, not an established clinical concern at approved human dosing.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative findings: None identified. The label's own hepatic-impairment data (mild-to-moderate hepatic impairment producing no meaningful pharmacokinetic change) is indirect counter-evidence against a clinically significant hepatotoxic effect at approved human dosing, though it does not directly measure oxidative-stress markers.
  • At-risk subgroups: None established at approved human dosing; this is a preclinical, mechanistic-tier signal only.

Regulatory status

Not addressed in the label as an oxidative-stress or hepatotoxicity finding; the label's hepatic-impairment language concerns clearance in patients with pre-existing liver disease, not sumatriptan-induced liver injury.

Population evidence

Tier B: a preclinical (in vitro or animal) study modeling sumatriptan-induced hepatotoxicity and testing protection by the antioxidants N-acetylcysteine and taurine, published in Advanced Pharmaceutical Bulletin, 2016. The exact model system, sumatriptan exposure level, and specific biomarkers measured were not retrievable from the sources accessible this session (the PubMed record page and the journal landing page both returned no extractable abstract text, and Crossref's metadata omitted the abstract); this is disclosed as a citation-completeness limitation rather than asserted detail.

Mechanism

Implied by the study's design and title: sumatriptan-induced hepatotoxicity mitigated by antioxidant co-treatment, consistent with an oxidative-stress-mediated component of injury at the exposure level tested. Not confirmed against a null comparator.

Counter-evidence held on record

Preclinical and mechanistic only; do not present as an established human hepatotoxicity or oxidative-stress risk from approved sumatriptan dosing. No antioxidant supplementation is indicated on this basis, and sumatriptan's acute, as-needed dosing pattern further limits any cumulative oxidative burden compared with medications taken daily.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

No sumatriptan-specific or triptan-class evidence of an effect on copper status was located, even after a dedicated repair pass.

Full detail, limits and 1 references

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: Both Step 7 conditions remain met after this repair pass: no Tier B or C evidence and no circulating claim. Assessment: this is now judged a genuine literature gap rather than primarily a tooling artifact, because the repair pass obtained a completed, multi-result Crossref search plus full-text access to the one sumatriptan-specific mechanistic study identified in this whole review, and neither showed any copper signal. Some channels (PubMed, Europe PMC and OpenAlex search) remained unusable this pass and were not independently re-verified beyond Crossref and the one full-text source; a future revision with working access to those channels should still re-check. Mechanistically, sumatriptan's low oral bioavailability reflects presystemic MAO-A metabolism, not a copper-dependent absorption or transporter pathway, which further reduces prior plausibility for this category.

Channels tried, repair pass 2026-09-29

FDA prescribing information (no copper-related interaction or effect documented, unchanged from original review). Crossref API, fresh query "sumatriptan copper" (10 results returned and individually reviewed: all were sumatriptan pharmaceutical-reference entries such as BNF, USP, and formulary listings, none involving copper or ceruloplasmin; a clean, completed negative). The sumatriptan-specific mechanistic study now read in full this pass (Khalili Fard et al. 2016, see Mitochondrial burden and Sources) names no copper-related biomarker. An OpenAlex single-record lookup on that same study's DOI was also checked for copper-related concepts and returned none.

Channels blocked, repair pass 2026-09-29

Direct proxy-level connections (confirmed via the agent-proxy status log) to Europe PMC, the Semantic Scholar API, the OpenAlex API, the Crossref API host itself, PubMed, and DailyMed each returned HTTP 403 policy denials when attempted outside WebFetch. Through WebFetch, PubMed's search-listing pages and Europe PMC's REST search endpoint returned HTTP 429 rate limiting after one attempt each; OpenAlex's search endpoint (distinct from its single-record lookup, which did succeed) also returned repeated HTTP 429. A DuckDuckGo HTML search fallback was blocked by that site's robots.txt rules.

Circulating claim

None found; see Fails verification for the consumer-database check.

Iron

Not graded — disclosed evidence gap

See study details

No sumatriptan-specific or triptan-class evidence of an effect on iron status was located, even after a dedicated repair pass.

Full detail, limits and 1 references

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: Both Step 7 conditions remain met. Assessment: genuine literature gap, on the strength of a completed, multi-result Crossref search and a full read of the one sumatriptan-specific mechanistic study in this dossier, neither of which showed an iron signal. As with Copper, PubMed, Europe PMC, and OpenAlex search remained unusable this pass and were not independently re-verified. Sumatriptan's poor oral bioavailability is attributable to first-pass MAO-A metabolism, not mucosal injury or an iron-competitive transport mechanism.

Channels tried, repair pass 2026-09-29

FDA prescribing information (no iron-related interaction, absorption effect, or renal-wasting mechanism documented, unchanged from original review). Crossref API, fresh query "sumatriptan iron hemoglobin" (10 results returned and individually reviewed: all addressed iron chelation therapy, hemoglobin biochemistry, or iron overload in thalassemia and hemochromatosis, with the one sumatriptan entry among them being an unrelated drug-reference listing; a clean, completed negative). The sumatriptan-specific mechanistic study read in full this pass (Khalili Fard et al. 2016) names no iron, hemoglobin, or ferritin-related biomarker.

Channels blocked, repair pass 2026-09-29

Same as disclosed under Copper: direct proxy-level connections to Europe PMC, Semantic Scholar, OpenAlex, Crossref, PubMed, and DailyMed returned HTTP 403 outside WebFetch; WebFetch-routed PubMed and Europe PMC search attempts returned HTTP 429; OpenAlex's search endpoint returned HTTP 429 after its single-record lookup succeeded; DuckDuckGo was blocked by robots.txt.

Circulating claim

None found; see Fails verification for the consumer-database check.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Not graded — disclosed evidence gap

See study details

No sumatriptan-specific or triptan-class evidence of a gut microbiome effect was located, even after a dedicated repair pass.

Full detail, limits and 1 references

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: Both Step 7 conditions remain met. Assessment: genuine literature gap, on the strength of a completed, multi-result Crossref search plus a full read of the one sumatriptan-specific mechanistic study in this dossier, neither of which showed a microbiome signal. Oral tablets do transit the gastrointestinal tract, but no antimicrobial, pH-altering, or motility-disrupting mechanism is documented in the label, and sumatriptan's acute, as-needed dosing pattern further limits plausibility of a sustained microbiome effect compared with a chronic daily medication.

Channels tried, repair pass 2026-09-29

Crossref API, fresh query "sumatriptan gut microbiome" (8 results returned and individually reviewed: all were general gut-microbiome science, inflammation, or aging literature with no connection to sumatriptan or any migraine drug; a clean, completed negative). FDA label reviewed again for any documented antimicrobial, pH-altering, or motility-disrupting mechanism (none found, unchanged from original review). The sumatriptan-specific mechanistic study read in full this pass (Khalili Fard et al. 2016) names no gut or intestinal-microbiome-related term.

Channels blocked, repair pass 2026-09-29

Same as disclosed under Copper and Iron: direct proxy-level connections to Europe PMC, Semantic Scholar, OpenAlex, Crossref, PubMed, and DailyMed returned HTTP 403 outside WebFetch; WebFetch-routed PubMed and Europe PMC search attempts returned HTTP 429; OpenAlex's search endpoint returned HTTP 429 after its single-record lookup succeeded; DuckDuckGo was blocked by robots.txt.

Circulating claim

None found; see Fails verification for the consumer-database check.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization, transient, vasoconstriction-mediated, acute-dose only

Yellow — Low

See study details

Acute sumatriptan dosing transiently reduces peripheral skeletal-muscle oxygen storage through the drug's own vasoconstrictive mechanism; this is a mechanism clarification, not a nutrient-mediated oxygen-delivery deficiency.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative findings: None identified in the sources reviewed; a dedicated null-result search for this specific finding was not completed due to fetch-channel rate limiting this session (disclosed).
  • At-risk subgroups: Patients who experience migraine with aura (per the cited study); patients with known vasospastic or coronary artery disease, per the label's separate cardiac-safety contraindications (a cardiac-safety concern, not a nutrient-status one).

Regulatory status

Not a labeled adverse reaction framed as an oxygen-delivery effect; the label separately warns of coronary vasospasm and non-coronary (including peripheral and gastrointestinal) vasospastic reactions from the same 5-HT1B/1D-mediated mechanism.

Population evidence

Human migraineurs studied with 31P magnetic resonance spectroscopy of skeletal muscle before and after sumatriptan dosing; reduced peripheral-muscle oxygen storage correlated with the drug's known side effects of limb heaviness and muscle ache, with greater susceptibility in patients who experience migraine with aura. Exact sample size was not confirmed from the sources accessible this session (see access note); this is disclosed as a citation-completeness limitation, not withheld.

Mechanism

Named and explicit: mild peripheral vasoconstriction, the same 5-HT1B/1D-receptor mechanism by which sumatriptan constricts cranial vasculature therapeutically and by which it produces its labeled cardiac and non-coronary vasospasm warnings. This is the drug's own intended pharmacologic action expressed peripherally, not an independent nutrient-status problem.

Counter-evidence held on record

This is sumatriptan's own intended vasoconstrictive mechanism showing up peripherally, not anemia, hypoxia, or a nutrient-mediated oxygen-carrying deficiency. It tracks the drug's roughly 115-minute elimination half-life and is expected to resolve between doses given sumatriptan's acute, as-needed dosing pattern. No iron, B12, or other hematologic supplementation is indicated by this finding.

ATP production, same dataset as oxygen delivery, no independent signal

Yellow — Low

See study details

The only sumatriptan-specific source touching skeletal-muscle energy metabolism attributes its findings to vasoconstriction-driven reduced perfusion, not to a direct, independent effect on mitochondrial ATP synthesis.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative findings: None identified; not independently searched beyond the shared source due to fetch-channel limitations this session.
  • At-risk subgroups: Same population as the Oxygen delivery/utilization entry.

Regulatory status

Not addressed in the label as an energy-metabolism effect.

Population evidence

Same human 31P-MRS study cited under Oxygen delivery/utilization; the source's own summary describes altered muscle energy-metabolism signals alongside the oxygen-storage finding (see Overlap map). No separate, independent dataset addressing ATP production specifically was located.

Mechanism

The study attributes its muscle energy-metabolism findings to mild peripheral vasoconstriction reducing local perfusion, the drug's own intended pharmacologic action, not to direct mitochondrial or ATP-synthesis toxicity of sumatriptan itself.

Counter-evidence held on record

Graded yellow because a Tier A source touches this category, per protocol, but the underlying evidence is the same hemodynamic mechanism already described under Oxygen delivery/utilization (see Overlap map). Treat the two entries as one physiological finding viewed from two angles, not as two independent confirmations. No energy-support supplementation (CoQ10, carnitine, creatine, or similar) is indicated on this basis.

How the body handles this medication

Metabolism
Predominantly metabolized by monoamine oxidase A (MAO-A) to an indole acetic acid metabolite with negligible pharmacologic activity; minor metabolites are not clinically significant.FDA prescribing information, Clinical Pharmacology
CYP450 induction or inhibition
None documented in the current label; sumatriptan's metabolism and elimination are not CYP450-dependent.FDA prescribing information, Clinical Pharmacology
Absorption and bioavailability
Oral tablet bioavailability is approximately 15%, mainly from presystemic (first-pass) metabolism and partly from incomplete absorption; subcutaneous bioavailability is approximately 97% relative to intravenous dosing; a fed-state meal increased Cmax by 15% and AUC by 12%, not considered clinically restrictive.Drugs.com professional monograph, sourced from FDA labeling
Elimination
Renal; approximately 22% excreted unchanged and 38% excreted as the inactive indole acetic acid metabolite; elimination half-life approximately 115 minutes following subcutaneous dosing.FDA prescribing information, Clinical Pharmacology
Protein binding
14% to 21% across the 10 to 1,000 ng/mL concentration range studied.FDA prescribing information, Clinical Pharmacology
Hepatic and renal impairment
Mild-to-moderate hepatic impairment produces no clinically meaningful pharmacokinetic change; severe hepatic impairment is contraindicated and has not been formally studied; renal impairment is not specifically addressed in the label's pharmacokinetic section.FDA prescribing information, Clinical Pharmacology and Contraindications
All references used above
  1. FDA prescribing information, IMITREX (sumatriptan succinate) tablets, injection, and nasal spray, and combination product labeling — Regulatory label. Supplement 31, approved 2025-12-09. NDA 020080/020132/020626.
  2. Drugs.com professional monograph, Imitrex (sumatriptan), Clinical Pharmacology section — Consumer/professional reference mirroring FDA label content; used to confirm the oral bioavailability percentage and food-effect data point not fully extracted from the primary label PDF in this session.
  3. Boska MD, Welch KM, Schultz L, Nelson J. Effects of the anti-migraine drug sumatriptan on muscle energy metabolism: relationship to side-effects. Cephalalgia. 2000. — Tier A. Human study, 31P magnetic resonance spectroscopy of skeletal muscle, sumatriptan administered to migraine patients. PMID 10817445. DOI 10.1046/j.1468-2982.2000.00009.x.Accessed via Crossref API bibliographic record (title, journal, year, DOI, and abstract summary). The direct PubMed record page returned no extractable abstract text in this session (empty/boilerplate content only); sample size and full methodological detail could not be independently confirmed and are flagged as such in the entries above.
  4. Khalili Fard J, Hamzeiy H, Sattari M, Eghbal MA. Protective Roles of N-acetyl Cysteine and/or Taurine against Sumatriptan-Induced Hepatotoxicity. Advanced Pharmaceutical Bulletin. 2016. — Tier B. Preclinical (in vitro or animal) hepatotoxicity model, sumatriptan named specifically. PMID 28101470. DOI 10.15171/apb.2016.077.Title, journal, year, authors, and DOI originally confirmed via PubMed search-listing and Crossref API; the direct PubMed record page returned no extractable abstract text in the original review session. Superseded during the 2026-09-29 repair pass: this article is Gold open access (CC-BY), confirmed via Unpaywall, and its full text was successfully read via the publisher's own PDF (apb.tbzmed.ac.ir) and independently corroborated via an OpenAlex single-record lookup by DOI. Full model system, sumatriptan concentration (5 mM, LC50 at 120 minutes), and all measured biomarkers are now confirmed and used in the Mitochondrial burden and Oxidative stress entries above; no mention of copper, iron, ferritin, ceruloplasmin, gut microbiome, or intestinal terms was found anywhere in the full text.
  5. Drugs.com interactions checker, sumatriptan — Consumer-facing drug-interaction database, checked for nutrient- or vitamin-depletion listings as part of the circulating-claim audit; 103 drug interactions listed, zero nutrient-related.
  6. WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index, code N02CC01 — Confirms ATC code N02CC01 for sumatriptan and lists defined daily doses by route (oral, subcutaneous, intranasal, rectal).
  7. PubMed search-listing pages, multiple queries: "sumatriptan mitochondrial"; "sumatriptan iron OR copper OR ferritin" (broken OR logic, returned unrelated results, noted and not used); "sumatriptan AND iron" (did not complete) — Search-listing results used to identify candidate Tier A/B sources and to document negative/incomplete searches for Copper, Iron, and Mitochondrial burden.Several follow-up PubMed queries in this family were interrupted by fetch-proxy rate limiting (HTTP 429) after the initial queries succeeded; incomplete queries are marked as such in the relevant ungraded entries above rather than treated as completed negative searches.
  8. Crossref API (api.crossref.org/works), multiple bibliographic queries combining sumatriptan or triptan-class terms with mitochondrial, oxidative-stress, gut-microbiome, iron, and copper/ceruloplasmin terms — Used to source the Boska 2000 and Khalili Fard 2016 bibliographic records, and to document explicitly negative results for iron, copper, and gut microbiome.
  9. Crossref API (api.crossref.org/works), 2026-09-29 repair pass, three fresh queries: "sumatriptan copper" (10 results, all sumatriptan pharmaceutical-reference entries, zero copper relevance), "sumatriptan iron hemoglobin" (10 results, all iron/hemoglobin biochemistry unrelated to sumatriptan), "sumatriptan gut microbiome" (8 results, all general microbiome science unrelated to sumatriptan) — All three queries completed cleanly via WebFetch and were individually reviewed result by result; all three are confirmed negative, not interrupted or partial.
  10. OpenAlex API (api.openalex.org), single-record lookups by PMID and by DOI for the Khalili Fard 2016 study — 2026-09-29 repair pass. Unlike OpenAlex's search endpoint (blocked this pass, see below), the per-record lookup endpoints (/works/pmid:28101470 and /works/doi:10.15171/apb.2016.077) succeeded via WebFetch and returned a reconstructed abstract and concept list, corroborating the publisher-PDF full text and confirming no copper, iron, or gut-microbiome-related concepts are associated with this work.
  11. Advanced Pharmaceutical Bulletin, publisher's own open-access PDF for Khalili Fard et al. 2016 — 2026-09-29 repair pass. Full text successfully retrieved directly from the journal's own server, bypassing the PubMed/PMC bot-verification interstitial encountered in the original review; used as the primary source for the quantitative data now in the Mitochondrial burden entry.
  12. Unpaywall API (api.unpaywall.org) — 2026-09-29 repair pass. Confirmed Gold open access, CC-BY status for the Khalili Fard 2016 study and surfaced the publisher-PDF and PubMed Central copy locations used above.
  13. Europe PMC (www.ebi.ac.uk/europepmc), Semantic Scholar API (api.semanticscholar.org), OpenAlex API (api.openalex.org) search endpoint, PubMed search-listing pages, DailyMed, DuckDuckGo HTML search — Named evidence-retrieval and fallback channels under this protocol, re-attempted during the 2026-09-29 repair pass with a dedicated tool budget.Direct proxy-level connections to Europe PMC, Semantic Scholar, OpenAlex, Crossref, PubMed, and DailyMed each returned HTTP 403 ("policy denial") outside WebFetch, confirmed against the agent-proxy status log at multiple timestamps through this repair pass, unchanged from the original review. Routed through WebFetch instead, a single Europe PMC REST search query and a single PubMed search-listing query each returned HTTP 429 rate limiting with an explicit instruction not to retry; OpenAlex's search endpoint returned HTTP 429 on two attempts after its separate single-record lookup endpoint had already succeeded (see above); a DuckDuckGo HTML search fallback for all three remaining ungraded categories was blocked by that site's robots.txt rules. This is a persistent, session-level and organization-level tooling limitation, disclosed per protocol both in the original review and again here, and should be re-attempted on any future revision of this dossier.